Admission Date:  [**2111-12-30**]              Discharge Date:   [**2112-1-21**]   Service: MEDICINE  Allergies: Patient recorded as having No Known Allergies to Drugs  Attending:[**First Name3 (LF) 2932**] Chief Complaint: transfer with cholangitis for ERCP  Major Surgical or Invasive Procedure: intubation, PICC line placement, ERCP   History of Present Illness: 85 yo female transferred from OSH.
She was brought to the OSH by family members on [**2111-12-29**] for a 2 week history of intermittent dark brown urine, abdominal discomfort, low-grade fevers, nausea, poor PO intake and jaundice.
GI and General Surgery were consulted and recommended immediate decompressive surgery and urgent ERCP.
Prior to transfer to [**Hospital1 18**], the patient received IVF crystalloid and colloid boluses, Zosyn, Flagyl, vancomycin, and hydrocortisone.
CVP was 13 and urine output was poor with a total volume of 250mL over 12-24 hours.
Past Medical History: 1. s/p colostomy 40 years ago [**2-26**] complication from EtOH use - no longer drinks EtOH, not related to cancer 2.
Sacral decubitus ulcer x 40y s/p surgical debridement and wound closure 3. s/p b/l cataracts surgery  Social History: lives alone [**Hospital1 1562**], was previously a heavy drinker, but not for 30 years, no tobacco or other drug use; usually walks at least 1 mile per day, does have short term memory deficits at baseline; son and daughter-in-law are the only living relatives  Family History: skin cancer - father, "heart arrythmia" - 2 sisters  Physical Exam: ADMISSION PHYSICAL EXAM: VS: 97.2 110/62 110 18 96% 2L NC GEN: tachypnic, jaundiced, NAD HEENT: PERRL, EOMI, +scleral icterus, MMM Cor: tachy, RR, soft heart sounds Lungs: tachypnic, mild crackles right base, no egophany Abd: hypoactive bowel sounds, diffuse TTP, soft/ND, no rebound or guarding; colostomy intact Ext: no c/c/e, 1+ distal pulses Skin: large sacral decubitus, stage II Neuro: alert and oriented to person, city, not date; CN II-XII intact, moving all 4 extremities  Pertinent Results: Laboratory studies on admission [**2111-12-30**] LACTATE-1.4 PT-14.9* PTT-27.5 INR(PT)-1.3 PLT COUNT-143 NEUTS-91.0 BANDS-0 LYMPHS-7.6 MONOS-1.4 EOS-0 BASOS-0 WBC-24.9 HGB-10.9 HCT-31.6 MCV-85 RDW-16.4 ALBUMIN-2.2 CALCIUM-7.6 PHOSPHATE-2.9 MAGNESIUM-2.6 CK-MB-4 cTropnT-<0.01 proBNP-[**Numeric Identifier 29256**] LIPASE-296 ALT(SGPT)-50 AST(SGOT)-71 CK(CPK)-20 ALK PHOS-167 AMYLASE-249 TOT BILI-9.6 DIR BILI-9.0 INDIR BIL-0.6 GLUCOSE-144 UREA N-30 CREAT-1.1 SODIUM-138 POTASSIUM-4.0 CHLORIDE-108 TOTAL CO2-23  Laboratory studies on discharge [**2112-1-21**] WBC-6.6 Hgb-11.0 Hct-35.2 MCV-96 Glucose-104 UreaN-15 Creat-1.7 Na-140 K-4.4 Cl-104 HCO3-26 AnGap-14 ALT-29 AST-47 AlkPhos-259 TotBili-3.1  Microbiology At [**Hospital3 **] Health Care wound with enterococci resistant to ampicillin, erythromycin, levofloxacin, PCN, vancomycin, sensitive to tetracycline.
A stent was placed across the common bile duct.
More proximally along the body on the left fluid collection measures 1.9 x 1.5 cm.
She was covered broadly with Zosyn/vancomycin, fluid resuscitated, and transferred to the general medical floor on [**1-3**].
A stent was placed [**12-31**] as mentioned above.
Following bile duct stent placement, her LFTs slow trended down (see discharge labs in results section).
Further work-up for other causes of LFT abnormalities include HBV panel (negative),  HCV Ab (negative), AMA (negative), HAV IgM (negative), and RUQ ultrasound (no evidence of hepatic/portal thrombosis).
For treatment of cholangitis, she was initially treated with vancomycin/Zosyn, subsequently changed to Cipro/vancomycin, completing a 20 day course.
The surgery service was consulted, who did not recommend drainage given their size and her improving clinical status.
The patient declined a renal ultrasound, but she continued to have good urine output.
If her creatinine improves, addition of afterload reduction may be considered.
Given she currently appears euvolemic, she is not on standing furosemide.
She should have daily weights as an outpatient; if she gains more than 2 pounds, addition of standing furosemide may be considered.
She was started on metoprolol for rate control, the dose of which can be adjusted as an outpatient.
She was started on low dose levothyroxine; repeat thyroid function tests in 6 weeks.
A nutrition consult was obtained, and she was started on supplements.
Nutritional supplementation options were discussed with the patient, who declined both tube feeds/G tube placement and TPN.
10) Full Code  Medications on Admission: MEDS at Home: Detrol - intermittently  MEDS on Transfer: Hydrocortisone 25mg IV q8h Zosyn 4.5g IV q8h Vancomycin 500mg IV q8h Flagyl 500mg IV q8h Protonix 40mg IV qD Demerol 25mg IV q3h PRN pain Hetastarch 500mL Ativan 0.5mg IV PRN  Discharge Medications: 1.
Heparin (Porcine) 5,000 unit/mL Solution Sig: 5000 (5000) units Injection TID (3 times a day).
Docusate Sodium 100 mg Capsule Sig: One (1) Capsule PO BID (2 times a day).
Pantoprazole 40 mg Tablet, Delayed Release (E.C.)
Senna 8.6 mg Tablet Sig: One (1) Tablet PO BID (2 times a day) as needed.
Bisacodyl 5 mg Tablet, Delayed Release (E.C.)
Zolpidem 5 mg Tablet Sig: One (1) Tablet PO HS (at bedtime) as needed.
Ipratropium Bromide 0.02 % Solution Sig: [**1-26**] neb Inhalation Q6H (every 6 hours) as needed for wheezing.
Levothyroxine 25 mcg Tablet Sig: One (1) Tablet PO DAILY (Daily).
Camphor-Menthol 0.5-0.5 % Lotion Sig: One (1) Appl Topical TID (3 times a day) as needed.
Albuterol Sulfate 0.083 % Solution Sig: One (1) neb Inhalation Q4H (every 4 hours) as needed.
Metoprolol Tartrate 25 mg Tablet Sig: One (1) Tablet PO BID (2 times a day).
Fluticasone 110 mcg/Actuation Aerosol Sig: Two (2) Puff Inhalation [**Hospital1 **] (2 times a day).
Reglan 10 mg Tablet Sig: One (1) Tablet PO every six (6) hours as needed for nausea.
Zofran 4 mg Tablet Sig: One (1) Tablet PO three times a day as needed for nausea.
Discharge Disposition: Extended Care  Facility: [**Location (un) **]  Discharge Diagnosis: Primary: cholangitis Secondary: enterococcus/klebsiella septicemia, hypothyroidism, systolic congestive heart failure, anemia   Discharge Condition: Stable.
Followup Instructions: 1) Biliary follow-up - you will be contact[**Name (NI) **] at your skilled nursing facility to schedule a repeat ERCP with common bile duct stent removal in mid-[**Month (only) 404**] (6 weeks following placement).
If you do not here from them, please call [**Telephone/Fax (1) 28098**] (Dr. [**Last Name (STitle) **] 2) CT scan: because of the fluid collections seen on your CT scan [**2112-1-6**], you should have a follow-up CT scan to ensure these are stable.
3) Primary care: Please follow-up with Dr. [**First Name8 (NamePattern2) **] [**First Name8 (NamePattern2) **] [**Last Name (NamePattern1) 4467**] ([**Telephone/Fax (1) 31293**]) within 1-2 weeks following discharge from the rehabilitation facility                                [**First Name8 (NamePattern2) **] [**Last Name (NamePattern1) **] MD [**MD Number(2) 2937**]  Completed by:[**2112-1-21**
